Intravitreal Bevacizumab for Neovascular Glaucoma
只有注册用户可以翻译文章
登陆注册
链接已保存到剪贴板
状态已完成
赞助商
Shahid Beheshti University of Medical Sciences
临床试验: NCT00384631
BioSeek: nct00384631
关键词
抽象
Several studies have confirmed high levels of vascular endothelial growth factor (VEGF) in eyes with neovascular glaucoma (NVG). The role of VEGF inhibitors in regression of other neovascular disorders such as wet-type age-related macular degeneration and diabetic macular edema has been described. We aim to evaluate the effect of three intravitreal injections of bevacizumab (Avastin) 2.5 mg versus a sham procedure for treatment of NVG. Outcome measures include intraocular pressure and extent of iris neovascularization. Both study arms will receive conventional treatment for NVG.
日期
| 最后验证: | 01/31/2008 |
| 首次提交: | 10/03/2006 |
| 提交的预估入学人数: | 10/03/2006 |
| 首次发布: | 10/05/2006 |
| 上次提交的更新: | 02/13/2008 |
| 最近更新发布: | 02/14/2008 |
| 实际学习开始日期: | 03/31/2006 |
| 预计完成日期: | 02/28/2007 |
状况或疾病
Neovascular
Glaucoma
干预/治疗
Other: 2
Drug: 1
相
-
手臂组
| 臂 | 干预/治疗 |
|---|---|
| Sham Comparator: 2 | Other: 2 0.1cc normal saline injection in the subconjunctival space repeated twice at monthly intervals |
| Experimental: 1 | Drug: 1 intravitreal injection of avastin 2.5mg repeated twice at monthly intervals |
资格标准
| 有资格学习的年龄 | 10 Years 至 10 Years |
| 有资格学习的性别 | All |
| 接受健康志愿者 | 是 |
| 标准 | Inclusion Criteria: - Clinical diagnosis of NVG - Vision less than 20/200 - age 10-80 years Exclusion Criteria: - Uncontrolled Blood Pressure - History of thromboembolism - Congestive Heart Failure - Renal Failure - Pregnancy or Lactation - Active ocular or periocular infection - No light perception |
结果
主要结果指标
1. Change in intraocular pressure [6 months]
2. Change in extent of iris neovascularization [6 months]
次要成果指标
1. Best corrected visual acuity [6 months]
